Exagen (NSD:XGN) is set to announce its quarterly earnings on Monday, March 20th, after the market closes. Investors are eagerly waiting for the results as analysts predict that the company will post earnings of ($0.74) per share for the quarter.
If you’re interested in hearing more about Exagen’s earnings report, you can register for the company’s conference call by following website.
Exagen Price Performance: Moving Averages, Highs, and Lows
On Monday, XGN opened at $2.43. The company has a 50-day moving average of $2.67 and a 200-day moving average of $2.90. Exagen has a 1-year low of $2.10 and a 1-year high of $9.44.
Exagen’s market capitalization is $39.51 million, and it has a P/E ratio of -1.07 and a beta of 1.26. The company also has a debt-to-equity ratio of 0.50, a quick ratio of 7.24, and a current ratio of 7.24.
Institutional Trading of Exagen: Who’s Buying and Selling?
Several large investors have recently bought and sold shares of Exagen. State Street Corp increased its holdings in the company by 3.6% in the first quarter, while Brinker Capital Investments LLC raised its position by 30.6%. Dimensional Fund Advisors LP also boosted its holdings in shares of Exagen by 50.1% during the first quarter.
Millennium Management LLC purchased a new position in shares of Exagen during the second quarter valued at about $457,000. UBS Group AG also grew its position in Exagen by 3.9% during the third quarter. Overall, 53.90% of the stock is owned by institutional investors.
Wall Street Analyst: What Do They Think?
Several analysts have weighed in on Exagen’s stock price. Cowen lowered their target price on shares of Exagen to $7.00, while BTIG Research dropped their target price from $10.00 to $7.00 and set a “buy” rating on the stock in a research report.
Canaccord Genuity Group also reduced their price target on shares of Exagen from $8.00 to $7.00 and set a “buy” rating for the company. Finally, Canaccord Genuity Group cut their price objective on shares of Exagen from $8.00 to $7.00 and set a “buy” rating on the stock in a research report.
Investors are eagerly awaiting Exagen’s upcoming quarterly earnings report. The company has had a fluctuating performance over the past year, with a 50-day moving average of $2.67 and a 200-day moving average of $2.90. Additionally, several large institutional investors have bought and sold shares of Exagen, and Wall Street analysts have weighed in on the stock with mixed opinions.
Exagen Inc Stock Analysis
Analysts Predict Strong Buy with Average Target Price of $7.00. Exagen Inc’s future seems promising based on the latest stock forecasts from three leading analysts in the industry. According to their projections, the average analyst target price for Exagen Inc. over the next 12 months is USD 7.00. This indicates a potential upside of approximately 188.6% from the current market price of USD 2.43.
Strong Buy Rating from Analysts
What’s more, Exagen Inc’s average analyst rating is Strong Buy, which suggests a favorable outlook for the company’s future performance. This rating is based on the consensus of three leading analysts who have carefully evaluated the stock’s current position and growth potential.
Slightly Bearish Analysis by Stock Target Advisor
On the other hand, Stock Target Advisor’s own stock analysis of Exagen Inc is Slightly Bearish. The analysis is based on three positive signals and five negative signals. While this may seem concerning at first glance, it’s important to note that stock analysis is not always an exact science and can often be subjective.
Recent Stock Performance
At the last closing, Exagen Inc’s stock price was USD 2.43. The company’s stock price has changed by +1.67% over the past week, -4.15% over the past month, and -69.01% over the last year. However, it’s worth noting that past performance does not necessarily predict future results.
Overall, Exagen Inc’s stock forecasts indicate a Strong Buy rating and a potentially significant upside. While there may be some negative signals in the analysis, it’s important to consider the positive outlook provided by leading analysts in the industry. As always, investors should perform their own due diligence and carefully evaluate the risks and potential rewards before making any investment decisions.